Sneller herstel van leukocyten door hematopoetische groeifactor bij patienten met door chemotherapie veroorzaakte granulocytopenie en koorts, maar geen kortere opnameduur

Translated title of the contribution: Faster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay

E. Vellenga*, C. A. Uyl-De Groot, G. Stoter, B. Löwenberg, E. G. E. De Vries

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    2 Citations (Scopus)

    Abstract

    Objective. To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) used in addition to standard inpatient antibiotic therapy shortens period of hospitalization for fever and neutropenia associated with chemotherapy. Design. Randomized, placebo-controlled phase III trial. Setting. Haematology and oncology departments of six University Hospitals (Amsterdam (Vrije Universiteit), Groningen, Leiden, Maastricht, Nijmegen, Rotterdam)) and one National Cancer Center (Dr. Daniel den Hoed Kliniek, Rotterdam), the Netherlands. Method. Patients with a haematological (n = 47) or solid tumour (n = 87) who had fever (temperature > 38°C over 12 h observation period or > 38.5°C once) and neutropenia (neutrophil count < 0.5 x 109/l) after chemotherapy were included in the study. Patients were randomly assigned to receive GM-CSF (5 μg/kg body weight per day, n = 65) or placebo (n = 69) in combination with broad-spectrum antibiotics. Patients remained on study until neutrophil count rose to ≤ 1.0 x 109/l and temperature was normal (< 37.5°C) for 2 consecutive days or at a white blood cell count of 10 x 109/l or more both followed by 24 hr observation period (hospitalization period). Results. Compared with placebo, GM-CSF accelerated the neutrophil recovery. Significantly higher neutrophil counts were observed at days 4 and 5 of treatment. No significant difference was observed with regard to median number of days < 1.0 x 109/l granulocytes (4 versus 4) or days of fever (3 versus 3). The median number of days patients were hospitalized while on study was comparable in the GM-CSF arm and placebo arm (6 (range 3-14) vs 7 (4-14) according to the intention-to-treat analysis (p > 0.05)). Conclusions. Addition of GM-CSF to the treatment of patients with fever and neutropenia following chemotherapy does not shorten the hospitalization period.

    Translated title of the contributionFaster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay
    Original languageDutch
    Pages (from-to)1650-1655
    Number of pages6
    JournalNederlands Tijdschrift voor Geneeskunde
    Volume140
    Issue number32
    Publication statusPublished - 10-Aug-1996

    Fingerprint

    Dive into the research topics of 'Faster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay'. Together they form a unique fingerprint.

    Cite this